A Novel Model of Tumor-Infiltrating B Lymphocyte Specific RNA-Binding Protein-Related Genes With Potential Prognostic Value and Therapeutic Targets in Multiple Myeloma

被引:2
作者
Zhang, JingJing [1 ,2 ]
He, Pengcheng [1 ]
Wang, Xiaoning [1 ]
Wei, Suhua [1 ]
Ma, Le [1 ]
Zhao, Jing [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hematol, Xian, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
关键词
multiple myeloma; tumor-infiltrating B lymphocyte; RNA-binding protein; prognostic signature; immune-related signature; immunotherapy; IMMUNE CONTEXTURE; CELLS; EXPRESSION; DEXAMETHASONE; LENALIDOMIDE; SENSITIVITY; BORTEZOMIB;
D O I
10.3389/fgene.2021.778715
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: RNA-binding proteins (RBPs) act as important regulators in the progression of tumors. However, their role in the tumorigenesis and prognostic assessment in multiple myeloma (MM), a B-cell hematological cancer, remains elusive. Thus, the current study was designed to explore a novel prognostic B-cell-specific RBP signature and the underlying molecular mechanisms.Methods: Data used in the current study were obtained from the Gene Expression Omnibus (GEO) database. Significantly upregulated RBPs in B cells were defined as B cell-specific RBPs. The biological functions of B-cell-specific RBPs were analyzed by the cluster Profiler package. Univariate and multivariate regressions were performed to identify robust prognostic B-cell specific RBP signatures, followed by the construction of the risk classification model. Gene set enrichment analysis (GSEA)-identified pathways were enriched in stratified groups. The microenvironment of the low- and high-risk groups was analyzed by single-sample GSEA (ssGSEA). Moreover, the correlations among the risk score and differentially expressed immune checkpoints or differentially distributed immune cells were calculated. The drug sensitivity of the low- and high-risk groups was assessed via Genomics of Drug Sensitivity in Cancer by the pRRophetic algorithm. In addition, we utilized a GEO dataset involving patients with MM receiving bortezomib therapy to estimate the treatment response between different groups.Results: A total of 56 B-cell-specific RBPs were identified, which were mainly enriched in ribonucleoprotein complex biogenesis and the ribosome pathway. ADAR, FASTKD1 and SNRPD3 were identified as prognostic B-cell specific RBP signatures in MM. The risk model was constructed based on ADAR, FASTKD1 and SNRPD3. Receiver operating characteristic (ROC) curves revealed the good predictive capacity of the risk model. A nomogram based on the risk score and other independent prognostic factors exhibited excellent performance in predicting the overall survival of MM patients. GSEA showed enrichment of the Notch signaling pathway and mRNA cis-splicing via spliceosomes in the high-risk group. Moreover, we found that the infiltration of diverse immune cell subtypes and the expression of CD274, CD276, CTLA4 and VTCN1 were significantly different between the two groups. In addition, the IC50 values of 11 drugs were higher in the low-risk group. Patients in the low-risk group exhibited a higher complete response rate to bortezomib therapy.Conclusion: Our study identified novel prognostic B-cell-specific RBP biomarkers in MM and constructed a unique risk model for predicting MM outcomes. Moreover, we explored the immune-related mechanisms of B cell-specific RBPs in regulating MM. Our findings could pave the way for developing novel therapeutic strategies to improve the prognosis of MM patients.
引用
收藏
页数:15
相关论文
共 57 条
  • [1] Gene Ontology: tool for the unification of biology
    Ashburner, M
    Ball, CA
    Blake, JA
    Botstein, D
    Butler, H
    Cherry, JM
    Davis, AP
    Dolinski, K
    Dwight, SS
    Eppig, JT
    Harris, MA
    Hill, DP
    Issel-Tarver, L
    Kasarskis, A
    Lewis, S
    Matese, JC
    Richardson, JE
    Ringwald, M
    Rubin, GM
    Sherlock, G
    [J]. NATURE GENETICS, 2000, 25 (01) : 25 - 29
  • [2] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
    Attal, Michel
    Lauwers-Cances, Valerie
    Hulin, Cyrille
    Leleu, Xavier
    Caillot, Denis
    Escoffre, Martine
    Arnulf, Bertrand
    Macro, Margaret
    Belhadj, Karim
    Garderet, Laurent
    Roussel, Murielle
    Payen, Catherine
    Mathiot, Claire
    Fermand, Jean P.
    Meuleman, Nathalie
    Rollet, Sandrine
    Maglio, Michelle E.
    Zeytoonjian, Andrea A.
    Weller, Edie A.
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    Facon, Thierry
    Avet-Loiseau, Herve
    Harousseau, Jean-Luc
    Moreau, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) : 1311 - 1320
  • [3] Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
    Bauer, Michael A.
    Ashby, Cody
    Wardell, Christopher
    Boyle, Eileen M.
    Ortiz, Maria
    Flynt, Erin
    Thakurta, Anjan
    Morgan, Gareth
    Walker, Brian A.
    [J]. HAEMATOLOGICA, 2021, 106 (03) : 736 - 745
  • [4] Substratification of patients with newly diagnosed standard-risk multiple myeloma
    Binder, Moritz
    Rajkumar, S. Vincent
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Hwa, Yi L.
    Zeldenrust, Steven R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Gonsalves, Wilson I.
    Kyle, Robert A.
    Kumar, Shaji K.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (02) : 254 - 260
  • [5] The oncogenic and tumor suppressive roles of RNA-binding proteins in human cancers
    Bitaraf, Amirreza
    Razmara, Ehsan
    Bakhshinejad, Babak
    Yousefi, Hassan
    Vatanmakanian, Mousa
    Garshasbi, Masoud
    Cho, William C.
    Babashah, Sadegh
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (09) : 6200 - 6224
  • [6] FASTKD1 and FASTKD4 have opposite effects on expression of specific mitochondrial RNAs, depending upon their endonuclease-like RAP domain
    Boehm, Erik
    Zaganelli, Sofia
    Maundrell, Kinsey
    Jourdain, Alexis A.
    Thore, Stephane
    Martinou, Jean-Claude
    [J]. NUCLEIC ACIDS RESEARCH, 2017, 45 (10) : 6135 - 6146
  • [7] Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
    Botta, Cirino
    Mendicino, Francesco
    Martino, Enrica Antonia
    Vigna, Ernesto
    Ronchetti, Domenica
    Correale, Pierpaolo
    Morabito, Fortunato
    Neri, Antonino
    Gentile, Massimo
    [J]. CANCERS, 2021, 13 (13)
  • [8] Interactions within the yeast Sm core complex:: from proteins to amino acids
    Camasses, A
    Bragado-Nilsson, E
    Martin, R
    Séraphin, B
    Bordonné, R
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (04) : 1956 - 1966
  • [9] A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
    Chauhan, Dharminder
    Tian, Ze
    Nicholson, Benjamin
    Kumar, K. G. Suresh
    Zhou, Bin
    Carrasco, Ruben
    McDermott, Jeffrey L.
    Leach, Craig A.
    Fulcinniti, Mariaterresa
    Kodrasov, Matthew P.
    Weinstock, Joseph
    Kingsbury, William D.
    Hideshima, Teru
    Shah, Parantu K.
    Minvielle, Stephane
    Altun, Mikael
    Kessler, Benedikt M.
    Orlowski, Robert
    Richardson, Paul
    Munshi, Nikhil
    Anderson, Kenneth C.
    [J]. CANCER CELL, 2012, 22 (03) : 345 - 358
  • [10] Molecular markers of endometrial carcinoma detected in uterine aspirates
    Colas, Eva
    Perez, Cristina
    Cabrera, Silvia
    Pedrola, Nuria
    Monge, Marta
    Castellvi, Josep
    Eyzaguirre, Fernando
    Gregorio, Jesus
    Ruiz, Anna
    Llaurado, Marta
    Rigau, Marina
    Garcia, Marta
    Ertekin, Tugce
    Montes, Melania
    Lopez-Lopez, Rafael
    Carreras, Ramon
    Xercavins, Jordi
    Ortega, Alicia
    Maes, Tamara
    Rosell, Elisabet
    Doll, Andreas
    Abal, Miguel
    Reventos, Jaume
    Gil-Moreno, Antonio
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (10) : 2435 - 2444